Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates through two main segments: Diagnostic Substances and Therapeutic Development Programs. It utilizes its Manocept platform to target the CD206 mannose receptor found on activated macrophages, which has applications in various diagnostic modalities such as PET imaging and intra-operative detection. Among its offerings is NAV4694, a PET imaging agent designed to aid in the assessment of Alzheimer’s disease and mild cognitive impairment. Additionally, Navidea is advancing other diagnostic substances, including Tc99m tilmanocept, and is engaged in various therapeutic development initiatives. The company has also established a collaboration with IMV Inc. to explore potential synergies between their immunotherapy platforms. Founded in 1983 and headquartered in Dublin, Ohio, Navidea Biopharmaceuticals was formerly known as Neoprobe Corporation before changing its name in 2012.